- Home
- HG vs NVCR Comparison
HG vs NVCR Comparison
Compare HG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HG
- NVCR
- Stock Information
- Founded
- HG 2013
- NVCR 2000
- Country
- HG Bermuda
- NVCR Jersey
- Employees
- HG N/A
- NVCR N/A
- Industry
- HG
- NVCR Medical/Dental Instruments
- Sector
- HG
- NVCR Health Care
- Exchange
- HG Nasdaq
- NVCR Nasdaq
- Market Cap
- HG 1.9B
- NVCR 3.2B
- IPO Year
- HG 2023
- NVCR 2015
- Fundamental
- Price
- HG $18.67
- NVCR $29.99
- Analyst Decision
- HG Buy
- NVCR Buy
- Analyst Count
- HG 7
- NVCR 5
- Target Price
- HG $22.00
- NVCR $33.40
- AVG Volume (30 Days)
- HG 317.6K
- NVCR 1.1M
- Earning Date
- HG 11-06-2024
- NVCR 02-20-2025
- Dividend Yield
- HG N/A
- NVCR N/A
- EPS Growth
- HG 537.51
- NVCR N/A
- EPS
- HG 4.48
- NVCR N/A
- Revenue
- HG $2,266,708,000.00
- NVCR $577,738,000.00
- Revenue This Year
- HG N/A
- NVCR $19.13
- Revenue Next Year
- HG $7.19
- NVCR $5.38
- P/E Ratio
- HG $4.15
- NVCR N/A
- Revenue Growth
- HG 68.94
- NVCR 14.63
- 52 Week Low
- HG $12.44
- NVCR $11.70
- 52 Week High
- HG $20.71
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- HG 47.32
- NVCR 58.14
- Support Level
- HG $18.38
- NVCR $29.62
- Resistance Level
- HG $19.24
- NVCR $32.06
- Average True Range (ATR)
- HG 0.54
- NVCR 1.80
- MACD
- HG -0.04
- NVCR -0.60
- Stochastic Oscillator
- HG 37.60
- NVCR 8.20
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in Lloyd's, Ireland, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.